Vaccine development (no licensed human vaccine as of 2026)
ChAdOx1 RVF — Phase 1 trial in Uganda (2026); safe and immunogenic
hRVFV-4s live attenuated — Phase 1 trial (Lancet Infect Dis, 2024); dose-escalation study showed safety and immunogenicity
Neither vaccine licensed yet; candidates remain in clinical trial phase
Supportive care evidence base
Systematic review (Rigby et al., Lancet Infect Dis, 2023) of standard of care for VHFs
Supportive care remains primary treatment across all high-priority VHFs
No strong evidence base for any specific antiviral in RVF
Blood product use guided by DIC protocol and clinical hemorrhage, not prophylactically
Public health considerations
Notification to WHO through IHR 2005 framework mandatory
Biosafety precautions for laboratory personnel (BSL-3/4)
Livestock vaccination during interepidemic periods reduces human outbreak risk
No human post-exposure prophylaxis protocol established
Patient Discharge Instructions
copy discharge instructions
Your diagnosis
You had Rift Valley Fever, a viral infection spread by mosquitoes and contact with infected animals
The infection is caused by a virus; antibiotics do not treat this illness
Most people recover fully, but some complications can develop weeks after the initial illness
Activity and rest
Rest and avoid strenuous activity until fully recovered
Expect fatigue and weakness to persist for 2 to 120 days in some cases
Avoid heavy lifting or vigorous exercise until your follow-up appointment clears you
Diet and hydration
Drink plenty of fluids (water, clear soups, oral rehydration solutions)
Avoid raw milk, raw blood, or undercooked meat from any animal
Eat small frequent meals if nausea persists
Medications
Take only acetaminophen (Tylenol/paracetamol) for fever or pain
Do not take ibuprofen, aspirin, naproxen, or any blood-thinning medications unless specifically prescribed
Mosquito and animal protection
Use DEET-containing mosquito repellent on exposed skin
Sleep under an insecticide-treated bed net
Avoid contact with livestock or wild animals until fully recovered
Wash hands thoroughly after any animal contact
Follow-up appointments
Return for repeat blood tests (liver function, kidney function, blood count) within 1 week
Ophthalmology (eye specialist) appointment within 2 weeks — eye complications can appear up to 3 weeks after the illness even if your eyes feel normal now
Neurology follow-up if any neurologic symptoms develop — brain complications can appear 2 to 3 weeks after the fever resolves
Return to the emergency department immediately for
Any new or worsening bleeding from any site (gums, nose, skin, stool, urine, vomit)
Jaundice (yellow skin or eyes) or dark tea-colored urine
Blurred vision, floaters, loss of vision, or eye pain
Confusion, severe headache, seizures, stiff neck, or unusual behavior
Decreased urination or no urination
Persistent vomiting preventing fluid intake
Fever returning after initial improvement
Increasing weakness or inability to walk
References
Guidelines and key sources
Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley Fever: Biology and Epidemiology. The Journal of General Virology. 2019. PMID 31310198
Primary biology and epidemiology reference; endemicity, transmission, immunity
Anywaine Z, Lule SA, Hansen C, Warimwe G, Elliott A. Clinical Manifestations of Rift Valley Fever in Humans: Systematic Review and Meta-Analysis. PLoS Neglected Tropical Diseases. 2022. PMID 35333856
Pooled clinical data: thrombocytopenia, leukopenia, hemorrhagic features, mortality rates
Javelle E, Lesueur A, Pommier de Santi V, et al. The Challenging Management of Rift Valley Fever in Humans: Literature Review of the Clinical Disease and Algorithm Proposal. Annals of Clinical Microbiology and Antimicrobials. 2020. PMID 31969141
Rigby I, Michelen M, Dagens A, et al. Standard of Care for Viral Haemorrhagic Fevers: A Systematic Review of Clinical Management Guidelines for High-Priority VHFs. The Lancet Infectious Diseases. 2023. PMID 36758568
Supportive care evidence base across VHFs; antiviral evidence review
Al-Hazmi M, Ayoola EA, Abdurahman M, et al. Epidemic Rift Valley Fever in Saudi Arabia: A Clinical Study of Severe Illness in Humans. Clinical Infectious Diseases. 2003. PMID 12539063
Landmark clinical description of severe RVF; organ failure characterization
Scharton D, Bailey KW, Vest Z, et al. Favipiravir (T-705) Protects Against Peracute Rift Valley Fever Virus Infection and Reduces Delayed-Onset Neurologic Disease Observed With Ribavirin Treatment. Antiviral Research. 2014. PMID 24486952
Key favipiravir vs ribavirin animal study; neurologic disease amplification with ribavirin
Kahlon SS, Peters CJ, Leduc J, et al. Severe Rift Valley Fever May Present With a Characteristic Clinical Syndrome. American Journal of Tropical Medicine and Hygiene. 2010. PMID 20207858
Anywaine Z, Hansen C, Warimwe GM, et al. Severe Morbidity and Hospital-Based Mortality From Rift Valley Fever Disease 2017–2020, Uganda. Virology Journal. 2024. PMID 38702807
Acute renal failure 41% of hospitalized cases; mortality data from Uganda cohort
Al-Hazmi A, Al-Rajhi AA, Abboud EB, et al. Ocular Complications of Rift Valley Fever Outbreak in Saudi Arabia. Ophthalmology. 2005. PMID 15691569
Leroux-Roels I, Prajeeth CK, Aregay A, et al. Safety and Immunogenicity of the Live-Attenuated hRVFV-4s Vaccine Against Rift Valley Fever in Healthy Adults. The Lancet Infectious Diseases. 2024. PMID 39068957
Phase 1 hRVFV-4s vaccine trial; first-in-human dose-escalation safety data
Anywaine Z, Serwanga J, Ggayi AM, et al. Safety, Tolerability, and Immunogenicity of the ChAdOx1 RVF Vaccine Against Rift Valley Fever Among Healthy Adults in Uganda. The Lancet Infectious Diseases. 2026. PMID 41237791
Chaput S, Driouich JS, Pastorino B, et al. Preclinical Efficacy of a Favipiravir and Nitazoxanide Combination Against Rift Valley Fever Virus. Antiviral Research. 2026. PMID 41936880
Combination antiviral preclinical data; additive efficacy against RVFV
Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management. JAMA. 2002. PMID 11980524
Biodefense and public health management framework for VHFs including RVF
CDC Yellow Book 2025. Post-Travel Evaluation of the Ill Traveler. https://www.cdc.gov/yellow-book/hcp/post-travel-evaluation
Travel medicine framework for febrile returned traveler evaluation
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.